Background Twitter is a microblogging service providing a platform for social networking. For medical information, Twitter is an interesting channel for sharing and spreading information and as an engagement platform for different stakeholders. Benefits and caveats of uncontrolled medical information must be carefully pondered, considering the...
-
2020 (v1)PublicationUploaded on: April 14, 2023
-
2020 (v1)Publication
Click here to listen to the Podcast.
Uploaded on: March 27, 2023 -
2019 (v1)Publication
Uncommon epidermal growth factor receptor (EGFR) mutations reported in non–small-cell lung cancer, accounting approximately 10%-15% of all EGFR mutations, are a heterogeneous group characterized by different clusters: exon 20 insertion and mutations, exon 18 mutations, and complex mutations. Although available data confirming the intrinsic...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Background: Nivolumab was the first immune checkpoint inhibitor approved for previously treated advanced non–small cell lung cancer (NSCLC). Before its introduction in the market, nivolumab was made available to NSCLC patients through an expanded access program (EAP). Here we present the Italian cohort of patients with non-squamous NSCLC...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Detection and treatment of patients with familial hypercholesterolemia (FH) starting from childhood is fundamental to reduce morbidity and mortality. The activity of National realities such as the LIPIGEN (LIpid transPort disorders Italian GEnetic Network) Paediatric Group, founded in 2018, is a milestone in this context. The aim of this...
Uploaded on: February 4, 2024 -
2020 (v1)Publication
Background: Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer...
Uploaded on: April 14, 2023 -
2024 (v1)Publication
Aims The availability of novel lipid-lowering therapies (LLTs) has remarkably changed the clinical management of homozygous familial hypercholesterolaemia (HoFH). The impact of these advances was evaluated in a cohort of 139 HoFH patients followed in a real-world clinical setting. Methods and results The clinical characteristics of 139 HoFH...
Uploaded on: July 21, 2024 -
2022 (v1)Publication
Pathology registers can be a useful tool to overcome obstacles in the identification and management of familial hypercholesterolemia since childhood. In 2018, the LIPIGEN pediatric group was constituted within the Italian LIPIGEN study to focus on FH subjects under 18 years. This work aimed at discussing its recent progress and early outcomes....
Uploaded on: July 24, 2024